Vyome Holdings Reports Revenue Growth and Increased Operating Expenses Following Merger

Vyome Holdings, Inc., formerly ReShape Lifesciences Inc., completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, resulting in a name change and a shift in business focus. The company, now a clinical-stage specialty pharmaceutical firm based in Cambridge, MA, is targeting immune-inflammatory and rare diseases. Vyome's lead program, VT-1953, a topical gel for malignant fungating wounds, is slated for FDA discussions regarding a pivotal Phase 3 trial design in the first half of 2026, following positive Phase 2 investigator-initiated trial results. The company also has ophthalmic and acne programs in development.

For the year ended December 31, 2025, Vyome Holdings reported revenue of $319,714, compared to $256,944 in 2024, primarily from licensing and service income related to its pharmaceutical segment in India. Cost of goods sold was $100,943 in 2025 and $61,974 in 2024, resulting in a gross profit of $218,771 and $194,970, respectively. Operating expenses significantly increased to $10.67 million in 2025 from $1.20 million in 2024, driven by higher research and development expenses ($588,258 vs. $285,391) and general and administrative costs ($2.37 million vs. $898,572), as well as $7.71 million in transactional fees related to the merger. The company's net loss for 2025 was $10.48 million, compared to $1.45 million in 2024.

Key operational developments include the completion of an investigator-initiated Phase 2 study of VT-1953 for malignant fungating wounds in December 2025, which showed statistically significant reduction in malodor. The company is also advancing its VT-1908 ophthalmic drops program towards clinical trials by the end of 2025. Employee headcount as of December 31, 2025, was 18, with 9 full-time and 9 part-time employees located in the U.S. and India.

Vyome Holdings anticipates discussions with the FDA regarding the Phase 3 trial design for VT-1953 in the first half of 2026 and plans to initiate clinical trials for VT-1908 by the end of 2025. The company is also exploring partnerships for licensing or co-developing VB-1953 in the U.S. and other markets. The company believes its existing cash and cash equivalents will be sufficient to fund all of its anticipated operating expenses, including clinical trial expenses, and capital expenditure requirements up to June 2027.